Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of Duodopa in patients with advanced Parkinson's Disease

Next Previous
Trial Profile

Efficacy and safety of Duodopa in patients with advanced Parkinson's Disease

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Jun 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levodopa/carbidopa (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GLORIA
  • Sponsors AbbVie

Most Recent Events

  • 19 Jun 2018 Results of a post-hoc analysis presented at the 4th Congress of the European Academy of Neurology
  • 27 Apr 2018 Results assessing the safety of Levodopa/carbidopa Intestinal Gel using data from this study and other phase III studies, presented at the 70th Annual Meeting of the American Academy of Neurology
  • 27 Apr 2018 Results of post- hoc analysis from the GLORIA registry presented at the 70th Annual Meeting of the American Academy of Neurology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top